NCT06088771View on ClinicalTrials.gov

Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

March 8, 2024

Primary Completion Date

April 15, 2026

Study Completion Date

April 22, 2027

Conditions
Non-Small Cell Lung Cancer
Interventions
BIOLOGICAL

Dupilumab

Dupilumab will be administered at the recommended initial dosage of 600 mg (two 300 mg injections) on Day 1.

BIOLOGICAL

Cemiplimab

Cemiplimab will be administered at the recommended dosage of 350 mg, as an intravenous infusion, over 30 minutes on Day 1.

Trial Locations (1)

10029

RECRUITING

Icahn School of Medicine at Mount Sinai, New York

All Listed Sponsors
lead

Icahn School of Medicine at Mount Sinai

OTHER